September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Galectin-1 ameliorates dry eye disease
Author Affiliations & Notes
  • Paula Kataguiri
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
  • Wei-Sheng Chen
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
    Cell, Molecular and Developmental Biology, Tufts University, Boston, Massachusetts, United States
  • Zhiyi Cao
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
  • Victor Sendra
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
  • Pedram Hamrah
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
  • Driss Zoukhri
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
    Diagnosis and Health Promotion, Tufts University, Boston, Massachusetts, United States
  • Kenneth Kenyon
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
  • M. Elizabeth Fini
    Institute for Genetic Medicine and Departments of Cell & Neurobiology and Ophthalmology, University of Southern California, South California, California, United States
  • Shinwu Jeong
    Institute for Genetic Medicine and Departments of Cell & Neurobiology and Ophthalmology, University of Southern California, South California, California, United States
  • Noorjahan A Panjwani
    Ophthalmology, Tufts University, Boston, Massachusetts, United States
    Developmental, Molecular and Chemical Biology, Tufts University, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Paula Kataguiri, None; Wei-Sheng Chen, None; Zhiyi Cao, None; Victor Sendra, None; Pedram Hamrah, None; Driss Zoukhri, None; Kenneth Kenyon, None; M. Elizabeth Fini, None; Shinwu Jeong, None; Noorjahan Panjwani, None
  • Footnotes
    Support  National Eye Institute Grants R01EY007088
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 425. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Paula Kataguiri, Wei-Sheng Chen, Zhiyi Cao, Victor Sendra, Pedram Hamrah, Driss Zoukhri, Kenneth Kenyon, M. Elizabeth Fini, Shinwu Jeong, Noorjahan A Panjwani; Galectin-1 ameliorates dry eye disease. Invest. Ophthalmol. Vis. Sci. 2016;57(12):425.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry eye disease (DED) is a prevalent multifactorial disease of tears and ocular surface, recently recognized as an inflammatory disease, that alters the corneal epithelial barrier and damages ocular surface. Galectins are a family of animal lectins capable of recognizing β-galactosides and they have emerged as potent immunoregulatory agents. Galectin-1 (Gal-1) is considered an anti-inflammatory galectin. In this study, we assess the role of Gal-1 in a murine model of DED.

Methods : The air-draft-plus-scopolamine protocol was used to induce desiccating stress. Scopolamine hydrobromide (1 mg in 0.1 ml of 1.5% hydroxyethyl cellulose/PBS) was subcutaneously injected, twice a day for 5 days with air flow from fans. To determine the role of endogenous Gal-1 in DED, desiccating stress was induced in Gal-1 knockout (KO) mice and wildtype (WT) mice. To determine the therapeutic potential of recombinant Gal-1 on dry eye disease, desiccating stress was induced in WT mice, and recombinant Gal-1 in PBS (10 µg/10µl) or PBS alone were injected subconjunctivally on alternate days beginning on day 0. To assess the corneal epithelial barrier function, corneal fluorescein staining was performed with standardized grading on days 0, 2 and 5 post-desiccating stress. Additionally, tear production was measured with phenol red impregnated cotton threads. At the end of the experiments, corneas were harvested and processed for whole-mount corneal staining with an anti-LYVE-1 antibody. Lymphangiogenic areas of the cornea were calculated using ImageJ. Data were analyzed using the Mann-Whitney U test.

Results : Compared to WT mice, Gal-1 KO mice had worse corneal epithelial barrier function on days 2 and 5 post-DS (N=20 for each group, p<0.001) as determined by corneal fluorescein staining. Conversely, subconjunctival injections of recombinant Gal-1 markedly improved corneal epithelial barrier function on day 5 post-desiccating stress (N=10 for each group, p<0.001). Lymphangiogenic areas were higher in Gal-1 KO mice than in WT mice (p<0.001) on day 5 post- desiccating stress. In contrast, lymphangiogenic areas were lower in recombinant Gal-1-treated mice than in PBS-treated mice (p<0.01) on day 5-post- desiccating stress.

Conclusions : Utilizing a standardized animal model, we have shown that galectin-1 plays an important role in modulating DED and that administration of recombinant galectin-1 might be a potential new strategy in treating DED.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×